Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
pain drug
Biotech
Werewolf transforms into Ambros via reverse merger
Werewolf’s hunt for strategic alternatives has ended with a deal that positions Ambros to take its lead candidate through to a filing for approval.
Nick Paul Taylor
Aug 21, 2026 9:50am
Lilly buys 4E to beef up its non-opioid pain pipeline
Jun 16, 2026 2:34pm
Ramaswamy-backed Ambros launches with $125M to develop pain med
Dec 16, 2025 1:32pm
Lilly lands next-gen pain asset in $1B SiteOne acquisition
May 27, 2025 11:30am
Lexicon feels the pain as non-opioid data underwhelm investors
Mar 3, 2025 9:52am
Tris shows its opioid alternative is less likely to be abused
Jan 28, 2025 10:53am
